Today: 7 February 2026
Subscribe

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·····
Why Lumentum stock is whipping around today as Wall Street gears up for earnings

Why Lumentum stock is whipping around today as Wall Street gears up for earnings

Lumentum shares rose 2.5% to $390.96 Friday after volatile trading, outpacing Morgan Stanley’s new $350 price target. The firm kept an “equal weight” rating, citing strong demand but cautioning on margins and supply constraints. Investors await second-quarter earnings on Feb. 3 for updates on profitability and capacity.
30 January 2026
·····
Air Products stock jumps 6% after earnings beat guidance — what APD investors watch next

Air Products stock jumps 6% after earnings beat guidance — what APD investors watch next

Air Products and Chemicals shares rose 6.2% to $271.89 after fiscal Q1 adjusted EPS reached $3.16, beating estimates and topping guidance. Revenue climbed 6% to $3.1 billion. The company held its FY2026 adjusted EPS forecast at $12.85–$13.15 and expects capex near $4 billion. Helium weakness continued to weigh on volumes and pricing, especially in Asia.
30 January 2026
····
Honeywell stock cools after earnings pop as breakup clock and 2026 outlook take center stage

Honeywell stock cools after earnings pop as breakup clock and 2026 outlook take center stage

Honeywell shares slipped 0.1% to $226.96 Friday, following a 5% surge after quarterly results. Fourth-quarter revenue rose 6.4% to $9.76 billion, missing forecasts, while adjusted EPS beat estimates at $2.59. Aerospace sales jumped 13.4% to $4.52 billion. Honeywell plans asset sales and a reporting overhaul in the first half of 2026.
30 January 2026
····
Danaher stock steadies near $220 after earnings slide as 2026 outlook comes into focus

Danaher stock steadies near $220 after earnings slide as 2026 outlook comes into focus

Danaher shares edged up 0.1% to $219.83 Friday after steep losses earlier in the week. The company reported Q4 revenue of $6.84 billion and adjusted EPS of $2.23, with 2026 earnings guidance in line with analyst forecasts. Investors remain cautious amid weak academic research funding and recent stock swings. Vanguard disclosed an 8.63% stake in Danaher as of Dec. 31.
30 January 2026
········
Moog stock price jumps on record quarter, raised 2026 outlook and dividend boost

Moog stock price jumps on record quarter, raised 2026 outlook and dividend boost

Moog shares jumped 6.4% to $306.57 after the company posted record quarterly sales of $1.1 billion and raised its 2026 outlook. Bookings reached $2.3 billion, pushing backlog up 30% to $3.3 billion. The company lifted its quarterly dividend 3% to $0.30 per share. Free cash flow turned negative as Moog increased inventory and faced tariff pressures on margins.
30 January 2026
·····
AST SpaceMobile stock drops nearly 9% as Vanguard stake filing hits tape; traders eye late-February launch

AST SpaceMobile stock drops nearly 9% as Vanguard stake filing hits tape; traders eye late-February launch

AST SpaceMobile shares fell 8.7% to $111.50 Friday, swinging from a session high of $129.74 to a low of $109.04 on heavy volume. Vanguard disclosed a 7.68% stake in the company as of Dec. 31 in a regulatory filing. Investors are watching for the planned late-February BlueBird 7 satellite launch aboard Blue Origin’s New Glenn-3 rocket.
30 January 2026
·····
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
·····
Citigroup stock edges up as Trump taps Warsh for Fed, inflation data tests rate bets

Citigroup stock edges up as Trump taps Warsh for Fed, inflation data tests rate bets

Citigroup shares rose 0.4% to $115.65 Friday, outperforming a broader U.S. stock decline as investors eyed a midnight federal funding deadline and awaited next week’s jobs report. The move followed Donald Trump’s nomination of Kevin Warsh for Fed chair and a surprise jump in producer prices. Most major bank stocks were little changed. The Fed left rates steady this week at 3.50%-3.75%.
30 January 2026
·····
Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next

Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next

Procter & Gamble shares rose 1.1% to $151.58 Friday afternoon as investors moved into consumer-staples stocks amid inflation concerns and policy uncertainty. The S&P 500 fell 0.4% while the XLP staples ETF gained 1.2%. Senate obstacles raised the risk of a partial U.S. government shutdown before the midnight funding deadline. Investors await the Feb. 6 jobs report and further policy signals.
30 January 2026
········
1 … 214 215 216 217 218 … 2,710

Stock Market Today

Glencore share price steadies after Rio Tinto walks away — what to watch next week

Glencore share price steadies after Rio Tinto walks away — what to watch next week

7 February 2026
Glencore shares closed up 0.6% at 478.1 pence Friday, rebounding after a 7% drop following the collapse of merger talks with Rio Tinto. The company is expected to announce the sale of its Kazzinc stake soon and has signed a non-binding agreement with Orion for a potential $9 billion deal in the DRC. Investors await Glencore’s full-year results on Feb. 18 for further guidance.
RELX share price slides again as AI fears linger, results next week in focus

RELX share price slides again as AI fears linger, results next week in focus

7 February 2026
RELX closed down 4.6% at 2,145 pence in London on Friday, capping a volatile week ahead of its Feb. 12 full-year results. The company bought back 465,361 shares even as selling continued amid investor concerns over AI risks and pricing power. Peers Wolters Kluwer and Thomson Reuters also faced pressure. Markets await RELX’s outlook for 2026 trading.
Go toTop